Search

Indomethacin

Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, [A486] along with other acetic acid derivatives such as [diclofenac] … the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway.

Betaine

Currently, no treatments are available to correct the genetic causes of homocystinuria. … [L43105] Although it is present in many food products, the levels found there are insufficient to treat this condition.

Levomenthol

Forming clear or white waxy, crystalline substance, menthol is typically solid at room temperature. (-)-Menthol is the naturally-occurring and main form of menthol, and is assigned the (1R,2S,5R) configuration … Menthol mediates anesthetic properties and anti-irritating properties locally, thus it is widely used to relieve minor throat irritations.

Cabazitaxel

[A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel]. … [A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]

Technetium Tc-99m sulfur colloid

(intraperitoneal injection), is taken up by reticulocytes (intravenous injection), or enters the gastroesphageal tract (oral administration). … of reticuloendothelial cells for assessment of liver function, and studies of esophageal transit and gastroesophageal reflux.

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

Burosumab

This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. … X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood.

Denosumab

It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk … for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012.

Cetylpyridinium

Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays. … In these products, it generally mediates an antiseptic activity and protective action against dental plaque and reducing gingivitis.